Immediate discontinuance of the offending<unk>  or<unk> (s) is the first and critical step in treating any SCARs disorder. In the past, the mainstay treatment of severe cases of DRESS syndrome was the use, often at high-dosage, of<unk>  glucocorticoids, relying on the anti-inflammatory actions of these<unk> s to suppress the eosinophil- and T cell-induced tissue damage caused by the disorder. However, there have been no randomized control trials reporting on the<unk>  use of these<unk> s. Rather, there are suggestions that treatment with<unk>  glucocorticoids is associated with a higher incidence of relapse compared to topical glucocorticoid treatment and may be associated with a higher rate of opportunistic infection. Accordingly, less severe cases of this disorder may be better treated conservatively with general support and, where needed, topical glucocorticoids. Severer cases, particularly those involving significant internal organ involvement, may require<unk>  corticosteroids and efforts to support heart, kidney, lung, or other organ dysfunctions.
Drug reaction with eosinophilia and systemic symptoms
Mast cell activation syndrome
Hypotrichosis–lymphedema–telangiectasia syndrome
Tropical eosinophilia
Leukotriene receptor antagonist-associated Churg–Strauss syndrome
Bare lymphocyte syndrome type II
Pitt–Hopkins syndrome
Papular purpuric gloves and socks syndrome